Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: A systematic review and meta-analysis of recent randomized controlled trials

HIV Medicine

Volumn 13, Issue 3, 2012, Pages 148-155

  Pichenot, M ^a   Deuffic Burban, S ^b,c   Cuzin, L ^d   Yazdanpanah, Y ^a,b,c  

^a University Hospital of Tourcoing   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d CHU PURPAN   (France)

Author keywords

Chemokine (C C motif) receptor 5 (CCR5) inhibitors; HIV; Meta analysis; New antiretroviral drugs; Treatment experienced

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; MARAVIROC; PLACEBO; RALTEGRAVIR; TIPRANAVIR; VICRIVIROC;

ARTICLE; CD4 LYMPHOCYTE COUNT; DOSE RESPONSE; DRUG EFFICACY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MOTIF; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CCR5; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856577787     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00953.x     Document Type: Article

References (35)

1. Palella FJ, Delaney K, Moorman Aet al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Detels R, Muñoz A, McFarlane Get al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-1503.
3. Keiser O, Taffe P, Zwahlen Met al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18: 1835-1843.
4. Lohse N, Hansen AB, Pedersen Get al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
5. Jaggy C, von Overbeck J, Ledergerber Bet al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877-878.
6. Bhaskaran K, Hamouda O, Sannes Met al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51-59.
7. Cozzi-Lepri A, Phillips AN, Clotet Bet al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 2008; 22: 2187-2198.
8. Yazdanpanah Y, Fagard C, Descamps Det al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49: 1441-1449.
9. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at (accessed 5 May 2011).
10. Fatkenheuer G, Nelson M, Lazzarin Aet al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-1455.
11. Cooper DA, Steigbigel RT, Gatell JMet al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-365.
12. Gulick R, Lalezari J, Goodrich Jet al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
13. Steigbigel R, Cooper D, Kumar Pet al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-354.
14. Wilkin T, Ribaudo H, Gulick R. The Relationship of CCR5 Inhibitors to CD4 Cell Count Changes: A Meta-Analysis of Recent Clinical Trial. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract #800].
15. Song F, Altman DG, Glenny AM, Deeks JJ.Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472.
16. Green S, Higgins J. Cochrane handbook for systematic reviews of interventions 4.2.5. The Cochrane Collaboration. Available at (accessed 5 May 2011).
17. Moher D, Liberati A, Tetzlaff J, Altman D.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
18. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego: Academic Press, 1985.
19. Hedges LV, Vevea JL.Fixed- and random-effects models in meta-analysis. Psychol Methods 1998; 3: 486-504.
20. DerSimonian R, Laird N.Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
21. Gulick R, Su Z, Flexner Cet al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 15: 304-312.
22. Saag M, Goodrich J, Fätkenheuer Get al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199: 1638-1647.
23. Suleiman J, Zingman BS, Diaz RSet al. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010; 201: 590-599.
24. Gathe J, Diaz R, Fatkenheuer Get al. Phase 3 Trials of Vicriviroc in Treatment-experienced Subjects Demonstrate Safety but Not Significantly Superior Efficacy over Potent Background Regimens Alone. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract #54LB].
25. Nelson M, Arastéh K, Clotet Bet al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40: 404-412.
26. Katlama C, Haubrich R, Lalezari Jet al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-2300.
27. Cohen C, Berger D, Blick Get al. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS 2009; 23: 423-426.
28. Hicks C, Cahn P, Cooper Det al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-475.
29. Clotet B, Bellos N, Molina Jet al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-1178.
30. Lazzarin A, Campbell T, Clotet Bet al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
31. Madruga JV, Cahn P, Grinsztejn Bet al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
32. Egger M, May M, Chene Get al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
33. Soriano V, Geretti A, Perno Cet al. Optimal use of maraviroc in clinical practice. AIDS 2008; 22: 2231-2240.
34. Stepanyuk O, Chiang TS, Dever LLet al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009; 23: 1911-1913.
35. Wilkin T, Lalama C, Tenorio Aet al. Maraviroc (MVC) Intensification for Suboptimal CD4+Response Despite Sustained Virologic Suppression: ACTG 5256. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract #285].